I-Mab

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.

SHANGHAI and GAITHERSBURG, Md. , Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the "Board") approved a motion to pursue the listing of the Company's ordinary shares on The Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Dual Listing").

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited

SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of its proprietary CD73 antibody uliledlimab (also known as TJD5) in combination with atezolizumab (Tecentriq®) in patients with ovarian cancer and other selected advanced or metastatic solid tumors.

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors

The mean of analysts' price targets for IMab Sponsored ADR (IMAB) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?

I-Mab (NASDAQ: IMAB) has collaborated with Jumpcan Pharmaceutical Group to develop, manufacture, and commercialize eftansomatropin alfa (TJ101) in mainland China. Eftansomatropin alfa is I-Mab's long-acting recombinant human growth hormone.

I-Mab Shares Gain On Licensing Pact For Its Human Growth Hormone In China

The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa Jumpcan will pay I-Mab for a total of up to RMB 2.016 billion (approximately $315 million), including the upfront payment of RMB 224 million (approximately $35 million) ; this partnership deal represents one of the largest regarding China biopharma market The partnership marks another critical milestone for I-Mab's transformation towards commercialization and bringing this transformative treatment option for patients in need Investors and analysts are invited to join the conference call on November 10 at 8:00 a.m. ET SHANGHAI and GAITHERSBURG, MD.

I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa

Preclinical d ata of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea , Nov. 9, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a clinical-stage biotech developing bispecific antibody technology for immune-oncology and neurodegenerative diseases, today jointly announced preclinical data of their 4-1BB bispecific antibodies at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC

SHANGHAI and GAITHERSBURG, Md., Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has entered into a strategic collaboration with Roche Diagnostics, a global leader in in vitro diagnostics industry, to co-develop companion diagnostics (CDx) solutions for I-Mab's innovative pipeline, at the Fourth China International Import Expo (CIIE) in Shanghai.

I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE

Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie Initial clinical results of lemzoparlimab in combination with rituximab in NHL will be presented at the ASH 2021 Annual Meeting I-Mab to host a call for investors on December 14, 2021, at 8:00 a.m. ET SHANGHAI and GAITHERSBURG, Md.

I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021

SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in November.

I-Mab Announces Upcoming Participation at November Conferences

SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the appointment of John Long as the Company's Chief Financial Officer and Jielun Zhu as the Company's Chief Strategy Officer, both effectively immediately.

I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments

I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors across China. I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021.

I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China

-  I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growing San Diego biotech hub -  The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&D Center for global drug development SHANGHAI and GAITHERSBURG, Md., Oct. 22, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will establish a new site focusing on Translational Medicine and Formulation Research in San Diego.

I-Mab Expands U.S. Footprint with New R&D Site in San Diego

SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the IND submission for the initiation of phase 2 clinical trial of efineptakin alfa (also known as TJ107/GX-I7/NT-I7) in combination with PD-1 antibody in patients with advanced solid tumors, including triple-negative breast cancer (TNBC) as well as head and neck cancers.

I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 New IND application for combination of felzartamab with another I-Mab clinical asset as a potential first-line treatment for MM is planned in Q4 2021 SHANGHAI and GAITHERSBURG, Md., Oct. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it has completed the patient enrollment of the phase 3 clinical trial of human CD38 antibody felzartamab (also known as TJ202) in combination with lenalidomide as a second-line therapy in patients with multiple myeloma (MM).

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China

Alpine Immune Sciences

Bioventus

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

3 Small Biotech Stocks in Focus on World Arthritis Day

SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a South Korean biotech specializing in bispecific antibody technology, jointly announced that data from the preclinical studies of TJ-CD4B/ABL111 and TJ-L14B/ABL503, will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021), taking place November 12 – 14, 2021.

I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October.

I-Mab Announces Upcoming Participation at October Conferences

The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021 The current U.S. NHL clinical trial has now expanded to include clinical sites in China as an international multi-center clinical trial, which will potentially lead to a registrational trial in China upon approval by the NMPA The on-going clinical trial of lemzoparlimab in combination with AZA for AML/MDS is on track for completion of patient enrollment by Q4 2021, which will potentially lead to a registrational trial in China upon approval by the NMPA NMPA has recently approved the IND application for a phase 2 clinical trial of lemzoparlimab in combination with toripalimab in patients with advanced solid tumors SHANGHAI and GAITHERSBURG, Md., Sept. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced multiple clinical advancements of its anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4).

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab

A year after I-Mab (NASDAQ: IMAB) made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie Inc (NYSE: ABBV), the biotech is reportedly holding talks with big pharma players about partnerships and potential investment. Bloomberg broke the news of the "early talks" with global biopharma companies citing people familiar with the matter.

I-Mab In Talks With Pharma Giants About Partnership, Stake Sale: Bloomberg

The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial for enoblituzumab in solid tumors. The trial will evaluate enoblituzumab combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with selected solid tumors in China.

Why Are I-Mab Shares Trading Higher On Tuesday?

MacroGenics

SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted the Company's IND application to initiate a phase 2 trial for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda®) in patients with selected solid tumors in China.

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

SHANGHAI and GAITHERSBURG, Md. , Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG (Environmental, Social and Governance) Index Series, in addition to the FTSE Global Equity Index Series ("GEIS").

I-Mab Added to FTSE ESG Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Equity Index Series ("GEIS"), following FTSE's most recent semi-annual review.

I-Mab Added to FTSE Russell Global Equity Index Series

I-Mab (IMAB) CEO Joan Huaqiong Shen on Q2 2021 Results - Earnings Call Transcript

13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 Felzartamab (TJ202/MOR202) is on track for Biologic License Application (BLA) submission in Q4 2021 and eftansomatropin alfa (TJ101) phase 3 trial on track for completion of patient enrollment and potential commercial collaboration Growing pipeline with eight highly differentiated and clinically advanced assets in phase 2/3, followed by next generation of immuno-oncology assets, including bi-specific antibodies in phase 1 or pre-clinical stage and novel drug candidates enabled by transformative technologies for unique drug properties, e.g. AI-guided targeting, antibody by mRNA delivery, intracellular targeting and tumor-site activation Inclusion of the MSCI China All Shares Index, preparation of potential dual listing on China's STAR Market, and receiving of a high rating from the MSCI ESG assessment (the highest newly initiated rating among China-based biotech companies) Progress in building the manufacturing and commercialization capabilities as part of Company's transformation to a global biopharma I-Mab to host conference calls and webcasts on August 31, 2021.

News for I-Mab Stock (IMAB)